Cargando…

The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

The CB(1) cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most abundant G protein-coupled receptor in the mammalian brain. In particular, the CB(1) receptor is highly expressed in the basal ganglia, mostly on terminals of medium-sized spiny...

Descripción completa

Detalles Bibliográficos
Autores principales: Blázquez, C, Chiarlone, A, Bellocchio, L, Resel, E, Pruunsild, P, García-Rincón, D, Sendtner, M, Timmusk, T, Lutz, B, Galve-Roperh, I, Guzmán, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563779/
https://www.ncbi.nlm.nih.gov/pubmed/25698444
http://dx.doi.org/10.1038/cdd.2015.11
_version_ 1782389333923201024
author Blázquez, C
Chiarlone, A
Bellocchio, L
Resel, E
Pruunsild, P
García-Rincón, D
Sendtner, M
Timmusk, T
Lutz, B
Galve-Roperh, I
Guzmán, M
author_facet Blázquez, C
Chiarlone, A
Bellocchio, L
Resel, E
Pruunsild, P
García-Rincón, D
Sendtner, M
Timmusk, T
Lutz, B
Galve-Roperh, I
Guzmán, M
author_sort Blázquez, C
collection PubMed
description The CB(1) cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most abundant G protein-coupled receptor in the mammalian brain. In particular, the CB(1) receptor is highly expressed in the basal ganglia, mostly on terminals of medium-sized spiny neurons, where it plays a key neuromodulatory function. The CB(1) receptor also confers neuroprotection in various experimental models of striatal damage. However, the assessment of the physiological relevance and therapeutic potential of the CB(1) receptor in basal ganglia-related diseases is hampered, at least in part, by the lack of knowledge of the precise mechanism of CB(1) receptor neuroprotective activity. Here, by using an array of pharmacological, genetic and pharmacogenetic (designer receptor exclusively activated by designer drug) approaches, we show that (1) CB(1) receptor engagement protects striatal cells from excitotoxic death via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin complex 1 pathway, which, in turn, (2) induces brain-derived neurotrophic factor (BDNF) expression through the selective activation of BDNF gene promoter IV, an effect that is mediated by multiple transcription factors. To assess the possible functional impact of the CB(1)/BDNF axis in a neurodegenerative-disease context in vivo, we conducted experiments in the R6/2 mouse, a well-established model of Huntington's disease, in which the CB(1) receptor and BDNF are known to be severely downregulated in the dorsolateral striatum. Adeno-associated viral vector-enforced re-expression of the CB(1) receptor in the dorsolateral striatum of R6/2 mice allowed the re-expression of BDNF and the concerted rescue of the neuropathological deficits in these animals. Collectively, these findings unravel a molecular link between CB(1) receptor activation and BDNF expression, and support the relevance of the CB(1)/BDNF axis in promoting striatal neuron survival.
format Online
Article
Text
id pubmed-4563779
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45637792015-10-01 The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway Blázquez, C Chiarlone, A Bellocchio, L Resel, E Pruunsild, P García-Rincón, D Sendtner, M Timmusk, T Lutz, B Galve-Roperh, I Guzmán, M Cell Death Differ Original Paper The CB(1) cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most abundant G protein-coupled receptor in the mammalian brain. In particular, the CB(1) receptor is highly expressed in the basal ganglia, mostly on terminals of medium-sized spiny neurons, where it plays a key neuromodulatory function. The CB(1) receptor also confers neuroprotection in various experimental models of striatal damage. However, the assessment of the physiological relevance and therapeutic potential of the CB(1) receptor in basal ganglia-related diseases is hampered, at least in part, by the lack of knowledge of the precise mechanism of CB(1) receptor neuroprotective activity. Here, by using an array of pharmacological, genetic and pharmacogenetic (designer receptor exclusively activated by designer drug) approaches, we show that (1) CB(1) receptor engagement protects striatal cells from excitotoxic death via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin complex 1 pathway, which, in turn, (2) induces brain-derived neurotrophic factor (BDNF) expression through the selective activation of BDNF gene promoter IV, an effect that is mediated by multiple transcription factors. To assess the possible functional impact of the CB(1)/BDNF axis in a neurodegenerative-disease context in vivo, we conducted experiments in the R6/2 mouse, a well-established model of Huntington's disease, in which the CB(1) receptor and BDNF are known to be severely downregulated in the dorsolateral striatum. Adeno-associated viral vector-enforced re-expression of the CB(1) receptor in the dorsolateral striatum of R6/2 mice allowed the re-expression of BDNF and the concerted rescue of the neuropathological deficits in these animals. Collectively, these findings unravel a molecular link between CB(1) receptor activation and BDNF expression, and support the relevance of the CB(1)/BDNF axis in promoting striatal neuron survival. Nature Publishing Group 2015-10 2015-02-20 /pmc/articles/PMC4563779/ /pubmed/25698444 http://dx.doi.org/10.1038/cdd.2015.11 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0
spellingShingle Original Paper
Blázquez, C
Chiarlone, A
Bellocchio, L
Resel, E
Pruunsild, P
García-Rincón, D
Sendtner, M
Timmusk, T
Lutz, B
Galve-Roperh, I
Guzmán, M
The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title_full The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title_fullStr The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title_full_unstemmed The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title_short The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
title_sort cb(1) cannabinoid receptor signals striatal neuroprotection via a pi3k/akt/mtorc1/bdnf pathway
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563779/
https://www.ncbi.nlm.nih.gov/pubmed/25698444
http://dx.doi.org/10.1038/cdd.2015.11
work_keys_str_mv AT blazquezc thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT chiarlonea thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT bellocchiol thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT resele thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT pruunsildp thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT garciarincond thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT sendtnerm thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT timmuskt thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT lutzb thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT galveroperhi thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT guzmanm thecb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT blazquezc cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT chiarlonea cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT bellocchiol cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT resele cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT pruunsildp cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT garciarincond cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT sendtnerm cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT timmuskt cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT lutzb cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT galveroperhi cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway
AT guzmanm cb1cannabinoidreceptorsignalsstriatalneuroprotectionviaapi3kaktmtorc1bdnfpathway